BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 32305267)

  • 21. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
    Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
    J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors.
    Nakamura T; Kawauchi A; Oishi M; Ueda T; Shiraishi T; Nakanishi H; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T
    Int J Clin Oncol; 2016 Aug; 21(4):791-795. PubMed ID: 26701172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
    J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
    Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
    J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
    Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
    J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance.
    Hamilton RJ; Nayan M; Anson-Cartwright L; Atenafu EG; Bedard PL; Hansen A; Chung P; Warde P; Sweet J; O'Malley M; Sturgeon J; Jewett MAS
    J Clin Oncol; 2019 Aug; 37(22):1919-1926. PubMed ID: 30802156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
    Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
    Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
    [No Abstract]   [Full Text] [Related]  

  • 28. Is there still a place for retroperitoneal lymph node dissection in clinical stage 1 nonseminomatous testicular germ-cell tumours? A retrospective clinical study.
    Dieckmann KP; Anheuser P; Kulejewski M; Gehrckens R; Feyerabend B
    BMC Urol; 2018 Oct; 18(1):95. PubMed ID: 30367648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Retroperitoneal surgery in the treatment of germ-cell tumors of the testis: retroperitoneal lymph node dissection (RPLND)].
    Nicolai N; Necchi A; Piva L; Stagni S; Catanzaro MA; Biasoni D; Milani A; Torelli T; Salvioni R
    Urologia; 2010; 77(2):84-7. PubMed ID: 20890864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
    Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
    BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle: an update.
    Yoon GH; Stein JP; Skinner DG
    Urol Oncol; 2005; 23(3):168-77. PubMed ID: 15907716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management trends for men with early-stage nonseminomatous germ cell tumors of the testicle: An analysis of the National Cancer Database.
    Weiner AB; Pearce SM; Eggener SE
    Cancer; 2017 Jan; 123(2):245-252. PubMed ID: 27626903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors.
    McHugh DJ; Funt SA; Silber D; Knezevic A; Patil S; O'Donnell D; Tsai S; Reuter VE; Sheinfeld J; Carver BS; Motzer RJ; Bajorin DF; Bosl GJ; Feldman DR
    J Clin Oncol; 2020 Apr; 38(12):1332-1337. PubMed ID: 32109195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group.
    Gerdtsson A; Håkansson U; Törnblom M; Jancke G; Negaard HFS; Glimelius I; Halvorsen D; Karlsdóttir Á; Haugnes HS; Andreassen KE; Larsen SM; Holmberg G; Wahlqvist R; Tandstad T; Cohn-Cedermark G; Ståhl O; Kjellman A
    Eur Urol Oncol; 2020 Jun; 3(3):382-389. PubMed ID: 31506250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term results of laparoscopic retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testicular cancer.
    Neyer M; Peschel R; Akkad T; Springer-Stöhr B; Berger A; Bartsch G; Steiner H
    J Endourol; 2007 Feb; 21(2):180-3. PubMed ID: 17338618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
    Heidenreich A; Paffenholz P; Nestler T; Pfister D
    Oncol Res Treat; 2018; 41(6):370-378. PubMed ID: 29772568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early clinical stages of nonseminomatous testis cancer. Evaluation of the primary treatment and follow-up procedures of the SWENOTECA project.
    Klepp O; Olsson AM; Ous S; Nilsson S; Høisaether PA; Tveter K
    Scand J Urol Nephrol; 1991; 25(3):179-90. PubMed ID: 1658924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stage I nonseminomatous germ cell tumor of the testis: more questions than answers?
    Powles T
    Hematol Oncol Clin North Am; 2011 Jun; 25(3):517-27,viii. PubMed ID: 21570606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
    Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
    Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
    Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.